Charles River Laboratories International, Inc. (CRL) PEG Ratio: 0.04
Is Charles River Laboratories International, Inc.’s PEG ratio high or low?
Charles River Laboratories International, Inc.'s PEG ratio of 0.04 is 98% below its 5-year average of 2.58, near the low end of its 5-year range (0.04–8.48).
The PEG ratio for Charles River Laboratories International, Inc. (CRL) is 0.04. It is equal to its 12-month average by 0.00% (0.04).
CRL PEG Ratio Chart
CRL Average PEG Ratio Chart
CRL Current vs Average PEG Ratio Chart
CRL PEG Ratio Metrics
PEG RATIO
0.04
PEG RATIO AVG TTM
0.04
PEG RATIO AVG 3Y
0.51
PEG RATIO AVG 5Y
2.58
PEG RATIO AVG 10Y
3.05
PEG RATIO AVG 15Y
2.68
PEG RATIO AVG 20Y
2.25
CURRENT VS TTM AVG
+0.00%
CURRENT VS 3Y AVG
-92.16%
CURRENT VS 5Y AVG
-98.45%
CURRENT VS 10Y AVG
-98.69%
CURRENT VS 15Y AVG
-98.51%
CURRENT VS 20Y AVG
-98.22%
CRL Competitors' PEG Ratio
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Charles River Laboratories International, Inc. (CRL) | — | 0.04 | 0.04 | 0.51 | 2.58 |
| Bio-Rad Laboratories, Inc. (BIO) | $8.03B | 0.18 | 0.10 | 0.17 | 0.14 |
| Hims & Hers Health, Inc. (HIMS) | $6.46B | 1.21 | 0.83 | 0.68 | 0.68 |
| Align Technology, Inc. (ALGN) | $12.76B | 51.80 | 51.80 | 26.80 | 17.90 |
| Hologic, Inc. (HOLX) | $16.97B | 0.30 | 0.30 | 0.22 | 1.95 |
| Moderna, Inc. (MRNA) | $18.94B | 0.19 | 0.18 | 0.14 | 0.14 |
| BioNTech SE (BNTX) | $21.87B | 0.23 | 0.23 | 0.12 | 0.12 |
| Mettler-Toledo International Inc. (MTD) | $23.50B | 8.96 | 5.67 | 4.53 | 3.90 |
| Waters Corporation (WAT) | $24.19B | 75.62 | 75.62 | 40.78 | 27.51 |
| Veeva Systems Inc. (VEEV) | $27.37B | 1.42 | 1.47 | 5.64 | 5.88 |
Growth-Adjusted Valuation
PEG Ratio
0.04
P/E Ratio
N/A
Charles River Laboratories International, Inc. PEG Ratio Formula & Definition
PEG Ratio = PE Ratio / Earnings Growth Rate
The PEG ratio adjusts the PE ratio for expected earnings growth. A PEG near 1 is often considered fairly valued relative to growth.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Charles River Laboratories International, Inc. PEG Ratio FAQ
- What is the PEG ratio for Charles River Laboratories International, Inc. (CRL)?
- The PEG ratio for CRL stock is 0.04.
- Is Charles River Laboratories International, Inc.'s PEG ratio high or low?
- Charles River Laboratories International, Inc.'s PEG ratio of 0.04 is 98% below its 5-year average of 2.58, near the low end of its 5-year range (0.04–8.48).
- What is the TTM average PEG ratio for Charles River Laboratories International, Inc. (CRL)?
- The TTM average PEG ratio for CRL stock is 0.04.
- What is the 3Y average PEG ratio for Charles River Laboratories International, Inc. (CRL)?
- The 3Y average PEG ratio for CRL stock is 0.51.
- What is the 5Y average PEG ratio for Charles River Laboratories International, Inc. (CRL)?
- The 5Y average PEG ratio for CRL stock is 2.58.
- What is the 10Y average PEG ratio for Charles River Laboratories International, Inc. (CRL)?
- The 10Y average PEG ratio for CRL stock is 3.05.
- What is the 15Y average PEG ratio for Charles River Laboratories International, Inc. (CRL)?
- The 15Y average PEG ratio for CRL stock is 2.68.
- What is the 20Y average PEG ratio for Charles River Laboratories International, Inc. (CRL)?
- The 20Y average PEG ratio for CRL stock is 2.25.
Charles River Laboratories International, Inc. PEG Ratio History
| DATE | PEG RATIO |
|---|---|
| 2025-12-27 | 0.04 |
| 2022-12-31 | 0.98 |
| 2021-12-31 | 8.48 |
| 2020-12-31 | 0.81 |
| 2019-12-31 | 3.10 |
| 2018-12-31 | 0.29 |
| 2016-12-31 | 9.29 |
| 2015-12-31 | 1.39 |
| 2014-12-31 | 0.88 |
| 2013-12-31 | 4.17 |
| 2010-12-31 | 0.02 |
| 2008-12-31 | 0.01 |
| 2006-12-31 | 0.38 |
| 2005-12-31 | 1.63 |
| 2004-12-31 | 8.95 |
| 2003-12-31 | 0.34 |
| 2002-12-31 | 1.14 |
| 2000-12-31 | 0.47 |
Related Metrics
About Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- James C. Foster